However, to date, there is little evidence as to whether loss of APOB function will affect CHD risk,7,8 and a pharmacological test of this hypothesis with mipomersen seems unlikely because of the adverse effects of this therapy. This evidence concerns the gene APOB and coronary artery disorder.